Breaking News

Financial Report: Teva

May 1, 2014

Specialty revenues up 3% in the quarter

1Q Revenues: $5.0 billion (+2%)
1Q Earnings: $740 million  (+18%)
Generic revenues were $2.4 billion (including API sales of $179 million), up 3% in the quarter. Specialty medicine revenues were $2.1 billion, up 3%, driven by CNS and oncology products, partially offset by lower revenues of other specialty medicines. Copaxone sales were up 1% to $1.1 billion. Azilect sales were up 23% to $114 million. Nuvigil sales were $101 million, up 22%. Provigil sales were down 13% to $21 million. Treanda sales were up 5% to $180 million. OTC revenues were $269 million, down 12%, primarily due to lower sales in Eastern Europe.